Phase II Trial of Nintedanib in Patients With Advanced Esophagogastric Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 May 2017
At a glance
- Drugs Nintedanib (Primary)
- Indications Oesophageal cancer
- Focus Therapeutic Use
- 17 May 2017 Status changed from recruiting to active, no longer recruiting.
- 17 Jan 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 27 Sep 2014 New source identified and integrated (Memorial Sloan-Kettering Cancer Center:14-094).